The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Agree with you both, a man’s word is his bond and there’s no point giving ultra positive investor presentations if things don’t transpire as you say they will. However some investors/investor seem to buying large chunks of shares the question is whether this is based on any sensitive knowledge or just speculating on the fact that a digitisation of the NHS will happen in the near future.
Good to see production orders taken for Middle Eastern launch later this year. And further production order for Europe hopefully based on good initial online sales. It will be good to see it launched in UK always easier to get a feel of excitement and interest in product based on your country of residence.
https://www.colispharma.be/fr/problemes-d-erection/2605-eroxon-stimgel-4-tubes-unidoses.html
This pharmacy is sold out of the product. “Enrupture de stock” which depending on how much they had initially could be construed as a positive sign.
Yes seaview it’s remarkable that NHS trusts up and down the country are breaking their own secure guidance rules by using WhatsApp for so long. Images cannot be securely or properly viewed with this app which could lead to poor outcomes for patients. Tom gave a great investor presentation but he needs to deliver on what he outlined. He has the motivating factor of huge share options if he moves the s/p north, let’s hope he can deliver for us all.
That’s a pertinent point Shaz it may be referring to the new 2023 procurement government initiative that will apply to the CDC program and that is what FDBK hope to access with other trusts. I would certainly like to see a national rollout but with such unforeseen circumstances with just QVH I won’t be holding my breath.
It’s clear that government is aware of Feedback both in the UK and abroad. They were supported by DTI virtual trade mission to India. They know they have a great product. You would have thought they would want to encourage the company on the home turf so that they have a chance of bringing foreign revenues back into the country in the future. Competition is always fiercer abroad but you’d think the department of health would try and cut them some slack in the UK so that they can expand into India and other countries.
Barnacle it’s either QVH trust want to go through a more thorough due process or they are having doubts about FDBK’s operation we won’t know the answer until the contract is finally awarded.
Thanks Vascular for posting the info on the new public procurement act 2023. Anything that makes it easier for Feedback to obtain contracts is a plus let’s just hope they can pull it off. Just seems like grindingly slow progress atm
Looks like the answer Private Ryan to the number of tenders they are involved in is “ we will actively explore opportunities….” nothing in the present tense so probably only QVH atm. Which begs the question did TO mislead in the investor meet when he talked of multiple contracts before financial year end. Looks like South West contract probably scrapped as well. It’s the frustrating nature of nhs procurement procedures that is holding FDBK back.
Seaview with all the hard work FDBK have put into QVH this tender should be a given. I just hope they can get the ball rolling with the other CDC’s they have talked about. There does seem to be a delay in the reporting of these tenders the South West tender had a start date of March 15th and still no news. Perhaps just indicative of the way the NHS operates.
Whilst waiting for news is like waiting for the next moon landing at least FDBK are actively promoting bleepa to hopefully generate some sales
https://bleepa.com/community-diagnostic-centres
Thanks for your summary of today’s webinar dactions. It is clear why it will be the first line choice for treatment of ED due to all the positive differences between Eroxon and other tablet treatments. If for some reason that Eroxon doesn’t provide relief as reported by Driffield today then other alternatives are there to provide treatment. There is no other fast acting side effect free treatment on the market and this is why three leading experts in urology have confidence in making such a prediction for the uptake of Eroxon for ED sufferers. I’m sure Professor Ralph is not selling his shares in FUM if he has some.
Well thanks Driffield for being brave enough to write about your ED experience with Eroxon on this bb. It is good to hear the positive and negative sides with respect to the efficacy of Eroxon so that people can make informed decisions as regards their investment in FUM. It is a disappointment as FUM mentioned in the American trial that there were a mixture of mild, moderate and severe ED sufferers taking part. In any medical treatment there will always be statistical differences in the general population from a trial, medicine is not an exact science and it’s just unfortunate you didn’t find any benefit.